WSJ News Exclusive | How Novartis’s CEO Learned From His …
Sep 3, 2023 · After some deals and drug launches disappointed, Vas Narasimhan heard from investors—and hired an outspoken Wall Street analyst to manage strategy.
Novartis CEO 'Very Confident' on Sales Target, Doesn't Fear …
Nov 2, 2024 · REUTERS/Arnd Wiegmann/File Photo. ZURICH (Reuters) - Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday ...
Novartis CEO on Acquisitions, AI, Weight-Loss Drugs
Feb 16, 2024 · Novartis CEO Vas Narasimhan talks about acquisitions, AI and the future of weight-loss drugs. He speaks on "The David Rubenstein Show: Peer-to-Peer Conversations."
AI helping us make smarter, faster decisions, says Novartis R&D …
5 days ago · Vas Narasimhan is global head of drug development and chief medical officer at Novartis, and spoke to pharmaphorum at the company’s recent Q4 results conference. He says numerous pilot...
Novartis CEO Narasimhan’s Pay Almost Doubles to $18.8 Million
Jan 31, 2024 · Novartis AG Chief Executive Officer Vas Narasimhan’s compensation almost doubled to 16.25 million Swiss francs ($18.8 million) last year, even as the Swiss drugmaker tries to convince...
Vasant Narasimhan | Novartis
Since becoming CEO of Novartis in 2018, Vas has led a strategic and cultural transformation to build a fully focused medicines company—one that delivers high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D …
Novartis CEO explains 'prudent' 2024 guidance - Yahoo Finance
Jan 31, 2024 · Novartis CEO Vas Narasimhan joins Yahoo Finance Live to discuss the company’s outlook for 2024 and plans for beyond. The company forecast mid-single digit percentage net sales growth, an...
Watch CNBC’s full interview with Novartis CEO Vas Narasimhan
Oct 3, 2023 · Novartis CEO Vas Narasimhan joins 'Squawk on the Street' to discuss the company's new spin-off Sandoz, what a pure-play core pharmaceutical company means, and the idea of M&A to boost the...
Novartis and Molecular Partners report positive topline data from …
Jan 10, 2022 · “We are pleased that the results from the EMPATHY trial demonstrate the positive therapeutic effect of ensovibep, with the potential to be an important new treatment option to combat the rapidly evolving SARS-CoV-2 pandemic,” said Vas Narasimhan, CEO of Novartis.
Interview: Vas Narasimhan on Novartis' goal to lead in CAR-T
2 days ago · Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but...
- Some results have been removed